AnaBios
AnaBios is a San Diego-based preclinical CRO that supplies ethically procured human tissue and functional assays — including its CardioPRIME cardiac safety platform — to pharmaceutical, biotech, and academic clients for translational drug discovery.
- Company typePrivate
- Founded2008
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What AnaBios does
AnaBios is a San Diego-based preclinical contract research organization founded in 2008 that provides human tissue-based translational research services to pharmaceutical, biotechnology, and academic clients. The company procures ethically consented adult human tissue and primary cells through an extensive network of US hospitals and organ procurement organizations, and applies proprietary preservation methods to deliver specimens with RNA Integrity Number scores 25-40% higher than competing suppliers. Its core product is CardioPRIME, an adult human primary cardiomyocyte platform that simultaneously predicts drug-induced inotropic and pro-arrhythmia risk and has demonstrated 96% sensitivity and 100% specificity against a benchmarked reference set; the platform was further extended in February 2023 via a University of Louisville cardiac slice technology license.
AnaBios generates revenue through three principal streams: (1) preclinical contract research services (functional assays, translational studies, custom study design) billed on a quote-based, multi-year contract model with 24-48 hour response cycles; (2) one-time product sales of human tissue samples and primary cells (hepatocytes, precision-cut lung slices, heart, brain, kidney, DRG, and spinal cord tissue, plus acquired Cell Systems primary cells and media); and (3) technology licensing income. Distribution is primarily direct enterprise sales, supplemented by exclusive regional channel partnerships with FUJIFILM in Japan and Chayon Laboratories in South Korea. The company is privately held and backed by Ampersand Capital Partners, which invested in 2022 and financed the April 2023 acquisition of Cell Systems, adding a Kirkland, Washington operating site and a primary cell and cell culture media portfolio.
AnaBios' customer base includes global pharmaceutical enterprises (Sanofi, Amgen, Novartis, Cytokinetics, Regeneron, Continuum Therapeutics) collaborating on cardiac safety, heart failure, pain, pulmonary fibrosis, and COVID-19-related programs, supplemented by an annual Translational Research Grant program that engages academic researchers such as Gatehouse Bio and Auburn University. The company also holds an FDA grant (U01FD006879) for cardiomyocyte-based pro-arrhythmia biomarker development, and its VP of R&D co-chairs the ion channel group of the FDA's CiPA initiative, embedding AnaBios within US regulatory science for cardiac safety.
AnaBios firmographics
Firmographics- Name
- AnaBios
- Legal name
- AnaBios Corporation
- Website
- https://anabios.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AnaBios is a San Diego-based preclinical CRO that supplies ethically procured human tissue and functional assays — including its CardioPRIME cardiac safety platform — to pharmaceutical, biotech, and academic clients for translational drug discovery.
- Ownership category
- akta.pro rank
AnaBios industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- DMPK / ADME & Bioanalysis (HLAGAFAC)
Keywords
Where AnaBios is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
AnaBios business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: AnaBios provides preclinical contract research organization (CRO) services to pharmaceutical companies, biotech firms, and academic laboratories globally, conducting functional assays and translational studies on human tissue and cells to de-risk drug development programs.
- Human Tissue and Cell Products: Sale of high-quality human tissue samples (hepatocytes, heart tissue, DRG tissue, brain tissue, lung slices, kidney tissue, spinal cord) and primary cells from ethically consented donors, with proprietary preservation methods ensuring physiological function.
- Technology Licensing: Non-exclusive and exclusive technology transfer and license agreements for proprietary platforms, including the University of Louisville cardiac slice technology and CardioPRIME platform, for drug discovery applications.
- Regional Partnership Revenue: Revenue generated through exclusive regional partnerships such as FUJIFILM in Japan and Chayon Laboratories in South Korea, distributing AnaBios human tissue products and services through local partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Customized study pricing based on assay complexity, tissue type, and program stage |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
AnaBios product offering
Product offeringCore offering
AnaBios is a preclinical contract research organization that supplies ethically-sourced human tissue samples (hepatocytes, heart, lung, brain, kidney, DRG, spinal cord) and proprietary functional assay services for drug discovery and translational research. Its flagship CardioPRIME platform uses adult human primary cardiomyocytes to predict drug-induced inotropic and pro-arrhythmia risk, supported by pain, lung, kidney, and neurotoxicity assay services. It also distributes primary cells and media kits from its acquired Cell Systems subsidiary.
Product overview
AnaBios is a preclinical contract research organization (CRO) offering a unified platform of human tissue-based products and functional assay services for drug discovery and translational research. The core offerings include: (1) a portfolio of ethically-sourced human tissue products including hepatocytes, precision-cut lung slices, heart tissue, brain tissue, kidney tissue, DRG tissue, and spinal cord tissue, all procured through US-based hospitals and organ procurement organizations; (2) the proprietary CardioPRIME functional assay platform for cardiac safety assessment using adult human primary cardiomyocytes; (3) functional assay services spanning heart tissue assays, pain-related assays using DRG and spinal cord tissue, lung-related services, kidney-related services, and neurotoxicity assays; (4) acquired primary cell and media products from Cell Systems for 2D/3D and microfluidic research; and (5) licensed human cardiac slice technology from the University of Louisville. The company also operates a Translational Research Grant Award program providing tissue samples to academic researchers.
Differentiator
Problem solved
Functional benefit
Products and services
- CardioPRIME
Quantifiable outcome
- 96% sensitivity and 100% specificity in detecting torsadogenic drugs at 10-fold free therapeutic plasma concentration
- +4 more outcomes
Companies that use AnaBios
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
AnaBios technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
AnaBios partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- University of LouisvillecoreNon-exclusive technology transfer and license agreement with the University of Louisville for human cardiac slice technology developed by Dr. Tamer M. A. Mohamed. The technology enables researchers to maintain functioning human heart tissue in the laboratory for nearly two weeks. AnaBios incorporated this into its CardioPRIME platform for expanded capabilities in translational cardiac research.
- U.S. Food and Drug Administration (FDA)coreFDA awarded AnaBios grant U01FD006879 to develop a preclinical biomarker to identify pro-arrhythmia risk of potential drugs based on contractility measurements in human adult primary cardiomyocytes. FDA scientists have concluded that human tissue studies more accurately predict clinical outcomes than traditional preclinical models.
- SanoficorePartnership to develop a new treatment for atrial fibrillation, focusing on compounds designed to modulate a novel cardiac ion channel target. AnaBios acquired development and commercialization rights to an entire family of promising compounds addressing the global atrial fibrillation market (estimated $16.17 billion by 2020). CardioPRIME technology was employed to optimize efficacy and safety of the molecules.
- AmgencoreFirst-of-its-kind preclinical ex-vivo human cardiac research collaboration with Amgen, published in Frontiers in Physiology. Demonstrated that isolated human heart-based model combined with a newly-developed pro-arrhythmic score can differentiate between pro-arrhythmic and non-pro-arrhythmic compounds with greater predictivity than stem cell-derived models.
- FUJIFILMcoreExclusive Japan-only partnership where FUJIFILM distributes AnaBios human translational research services, leveraging its local presence and scientific infrastructure to serve pharmaceutical and biotechnology companies in Japan with high-quality human-relevant research services.
- Chayon LaboratoriescorePartnership with Chayon Laboratories to expand access to high-quality human tissue samples and specialized research services in South Korea. Combines AnaBios expertise in functional human tissue assays with Chayon Laboratories' tissue procurement and processing capabilities.
- CytokineticscoreCollaborative study co-authored with Cytokinetics published on bioRxiv, highlighting the power of human-relevant translational models to advance research in cardiac hypercontractility and heart failure with preserved ejection fraction (HFpEF). Work integrates mechanistic biochemistry with functional data from human cardiomyocytes and engineered heart tissues.
- Gatehouse BiominorGatehouse Bio CEO Dr. David W. Salzman won AnaBios 2024 Translational Research Grant Award, receiving up to $15,000 in human precision-cut lung slices to advance drug development in idiopathic pulmonary fibrosis using AnaBios human tissue models.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
AnaBios competitors and assessment
Company assessmentDirect peers
- BioIVT: BioIVT is a leading supplier of human biological specimens and tissues for research, including hepatocytes and other primary cells used in drug discovery. It is the most directly comparable competitor to AnaBios's human tissue product line, with overlapping customer base among pharma preclinical researchers.
- SEKISUI XenoTech: SEKISUI XenoTech specializes in human hepatocytes, subcellular fractions, and ADME/DMPK services for drug metabolism and toxicity studies. It directly competes with AnaBios in human hepatocyte supply and hepatic drug metabolism assay services.
- Inotiv: Inotiv is a preclinical contract research organization offering safety assessment, toxicology, and drug discovery services. It competes with AnaBios in cardiac safety and broader preclinical CRO services for pharmaceutical clients.
- Metrion Biosciences: Metrion Biosciences is a specialty CRO focused on cardiac safety pharmacology, ion channel screening, and electrophysiology services. It directly competes with AnaBios's CardioPRIME and ion channel cardiac safety offering.
Emerging players
- Ncardia: Ncardia develops iPSC-derived cardiomyocytes and other cell types for cardiac safety and drug discovery applications. It competes with AnaBios's primary tissue approach using scalable iPSC alternatives, particularly for customers prioritizing consistency and supply scalability.
- Cellular Dynamics International (FUJIFILM): FUJIFILM Cellular Dynamics is a leading iPSC-derived cell manufacturer including iCell cardiomyocytes for cardiac safety assessment. It is both an indirect competitor to AnaBios and the parent of FUJIFILM—AnaBios's exclusive Japan distribution partner.
- Axol Bioscience: Axol Bioscience manufactures iPSC-derived cardiomyocytes, neurons, and other cell types for drug discovery and safety assessment. It represents an emerging iPSC-based alternative to AnaBios's adult primary human tissue platform.
Broad incumbents
- Charles River Laboratories: Charles River is a large preclinical and clinical CRO offering safety assessment, cardiac safety, and discovery services, including legacy ChanTest and Icagen capabilities (AnaBios CCO Dr. Chris Mathes's prior employer). It competes broadly with AnaBios across pharma CRO services.
- Lonza: Lonza is a global CDMO and cell manufacturing leader offering primary cells, media, and broader preclinical services. It competes with AnaBios in primary cells and adjacent cell-based drug discovery services at a much larger scale.
- Eurofins Discovery: Eurofins Discovery is a broad preclinical CRO providing in vitro ADME, safety pharmacology, and drug discovery services. It competes with AnaBios in cardiac safety, ADME, and broader preclinical assay services through extensive global infrastructure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
AnaBios social profiles
Digital presenceAnaBios compliance and trust
Trust signalCompliance3 records
AnaBios financial estimates
Financial estimateRevenue estimate
Valuation estimate
AnaBios leadership team
Management profileNumber of profiles
Profiles7 records
AnaBios subsidiaries and ownership
Company hierarchySubsidiaries1 record
AnaBios funding detail
Funding detailFunding overview
Funding rounds10 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AnaBios M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AnaBios
What does AnaBios do?
AnaBios is a preclinical contract research organization that supplies ethically-sourced human tissue samples (hepatocytes, heart, lung, brain, kidney, DRG, spinal cord) and proprietary functional assay services for drug discovery and translational research. Its flagship CardioPRIME platform uses adult human primary cardiomyocytes to predict drug-induced inotropic and pro-arrhythmia risk, supported by pain, lung, kidney, and neurotoxicity assay services. It also distributes primary cells and media kits from its acquired Cell Systems subsidiary.
Is AnaBios a public or private company?
AnaBios is a private company. It is classified as private equity controlled and is currently operating.
When was AnaBios founded?
AnaBios was founded in 2008. It employs 11 to 50 people.
Where is AnaBios based?
AnaBios is headquartered in San Diego, United States, in the North America region.
How does AnaBios make money?
Four revenue lines are on record. Contract Research Services are the primary driver. The others are human Tissue and Cell Products, technology Licensing and regional Partnership Revenue.
Who are AnaBios's main competitors?
Direct peers on record are BioIVT, SEKISUI XenoTech, Inotiv and Metrion Biosciences. Emerging players are Ncardia, Cellular Dynamics International (FUJIFILM) and Axol Bioscience. Broad incumbents are Charles River Laboratories, Lonza and Eurofins Discovery.
Does AnaBios have an API?
No public API is recorded for AnaBios.
What industry is AnaBios in?
AnaBios's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 541714 and its SIC code is 8071.